CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aevi Genomic Medicine, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aevi Genomic Medicine, Inc.
435 Devon Park Drive
Suite 715
Phone: (610) 254-4201p:610 254-4201 Wayne, PA  19087-1946  United States Fax: (302) 636-5454f:302 636-5454

This company was Merged or Acquired on 2/3/2020.
This company ceased filing statements with the SEC on 2/14/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company's product candidates include AEVI-001 and AEVI-002. The Company's research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). .

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board Sol J.Barer 71 7/1/2012 7/1/2012
President, Chief Executive Officer, Director Michael F.Cola 59 9/13/2013 9/13/2013
Interim Chief Financial Officer MichaelMcInaw 32 6/1/2019 6/1/2019
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Aevi Genomic Medicine Europe BVBA/SPRL
GNMX
MDGN
4 additional Business Names available in full report.

General Information
Number of Employees: 14 (As of 12/31/2018)
Outstanding Shares: 77,713,782 (As of 12/20/2019)
Stock Exchange: NASD
Federal Tax Id: 980217544
Fax Number: (302) 636-5454


Copyright © 2021 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, October 28, 2021